Robyn Ward: Creating a standardised approach to cancer drug dosing in kidney dysfunction
Robyn Ward, Deputy Vice-Chancellor of Research and Enterprise and Senior Vice-President at Monash University, shared a post on LinkedIn:
“Cancer treatments are usually tested on people with healthy kidneys. However, many people with cancer have kidney problems due to other health conditions like diabetes or vascular disease.
How to properly assess kidney dysfunction and how to adjust the dose of cancer drugs have been intractable problems. As well as being uncertain about how to assess kidney disease, cancer doctors had no accurate guidance on how to adjust cancer drug doses based on kidney function, so patients receive the right amount of cancer medicine – neither too much nor too little.
Getting the dose right is crucial for achieving the best results from cancer treatments.
A group of international experts in cancer medicine, kidney medicine, pharmacy, and pharmacology came together to tackle these problems and create a standardised approach.
Our work is found in three new papers published in eClinicalMedicine:
‘Aligning kidney function assessment in patients with cancer to global practices in internal medicine‘
The resulting international guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) provides clear guidance on how to measure kidney function in patients with cancer and how to adjust doses of cancer drugs for patients with kidney issues.
These papers are a significant achievement because these basic issues in cancer treatment had been overlooked for over fifty years. This work paves the way for more inclusive cancer drug trials that represent all patients, and for more accurate prescribing of cancer medicines.
Special thanks go to the Cancer Institute NSW eviQ program and all the international collaborators for supporting this work and creating ADDIKD. This is a landmark achievement that Australia and the Cancer Institute NSW eviQ program should be rightly proud.”
Tracey O’Brien, Chief Cancer Officer and CEO of the Cancer Institute NSW, shared this post, adding:
“It’s fantastic to see this collaborative work published this week in eClinicalMedicine.
Reaching clinical guideline consensus, on an international scale, is virtually unheard of, but something the Cancer Institute NSW eviQ program team was proud to lead in order to develop the International Guideline for Anticancer Drug Dosing in Kidney Dysfunction.
Delivering consistent, best practice health care is key to saving lives. I’d like to thank the incredible eviQ team, including Robyn Ward and Shelley Rushton GAICD for leading this important work, in partnership with countless international collaborators.”
More posts featuring Tracey O’Brien.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023